Commit e5075627 authored by Jeff Webb's avatar Jeff Webb
Browse files

Cleaning up documentation for release.

parent 2f6fd672
Version 2.2.0 {#version}
Version 2.3.0 {#version}
=============
Our versioning follows the <a href="http://semver.org">Semantic Versioning 2.0.0</a> format.
......@@ -9,33 +9,44 @@ Our version number sematic is Major.Minor.Patch-ReleaseStage, where :
- PATCH changes when we make backwards-compatible bug fixes.
- Release Stage - We have extended this versioning with a <a href="http://en.wikipedia.org/wiki/Software_release_life_cycle">release stage</a>
## Pulse v2.2.0 (August 2019)
- - -
## Pulse v2.3.0 (January 2020)
- Software Architecture
- CMake integration improvements
- Improved Data Request API
- Scenario Execution Improvements
- Unified API for Engine Events
- MSVC Build Sped up
- Added a <i>Multiply</i> value setting, similar to <i>Increment</i>
- Created separate <i>Initial</i> and <i>Current</i> patient definitions
- Updated general math exponential functions to be more intuitive
- Physiology Models
- Added the ability to provide supplemental oxygen through a nasal cannula, simple mask, and nonrebreather mask.
- Updated vascular effects caused by respiratory pleural cavity imbalances, mainly to increased venous return resistance when the patient has a pneumothorax / collapsed lungs.
- Patient lung volumes are now determined using ideal body weight rather than actual body weight
- Significant respiratory model updates
- Changed standard respiration rate from 16 bpm to 12 bpm to better match standards in literature and validation
- Tweaked respiratory circuit for improved modeling
- Refactored the respiratory muscle driver with a new waveform
- Added a sigmoidal chest wall compliance model
- Refactored respiratory conditions and actions for improved restrictive and obstructive disease results and combined effects
- Added an ARDS condition
- Added a pulmonary fibrosis condition
- Added exacerbation action to degrade/improve respiratory conditions during simulations
- Renamed apnea action to dyspnea
- Refactored conscious respiration, leading to improved spirometry curves
- More/better validation
- Updated anesthesia machine circuit to use pressure sources for supplying gas, rather than flow sources to avoid issues with flow source pressure calculations
## Planned Improvements
- Black box circuit/compartment components
- Sepsis
- Hemorrhagic Shock
- %Respiratory fatigue and chronic condition exacerbation
- Surface area and efficiency parameters for the gas diffusion model
- Work of breathing and respiratory fatigue models
- A second order baroreceptor model
- Modularity improvements for system/model/circuit swapping
- Pediatric physiology prototype
- Official contribution plan for merge requests for methodology/model changes
- - -
@anchor known-issues
## Known Physiology Model Issues and Limitations
The following are known issues with the current version of the software:
- Lack of a full sympathetic/parasympathetic nervous system
- Extravascular fluid exchange model is incomplete
......@@ -46,11 +57,25 @@ The following are known issues with the current version of the software:
- Limited conversion and use within the engine
- Oxygen saturation drops too sharply
## Pulse v2.1.0 (Feb 2019)
- - -
## Pulse v2.2.0 (August 2019)
- Software Architecture
- CMake integration improvements
- Improved Data Request API
- Scenario Execution Improvements
- Unified API for Engine Events
- MSVC Build Sped up
- Physiology Models
- Added the ability to provide supplemental oxygen through a nasal cannula, simple mask, and nonrebreather mask.
- Updated vascular effects caused by respiratory pleural cavity imbalances, mainly to increased venous return resistance when the patient has a pneumothorax / collapsed lungs.
## Pulse v2.1.0 (February 2019)
- Software updates necessary for integration with Unity
## Pulse v2.0.0 (Jan 2019)
## Pulse v2.0.0 (January 2019)
- Software Architecture
- Converted ASCII file I/O to JSON (Compliant to Protobuf IDLs)
......
......@@ -237,7 +237,7 @@ The pharmacodynamic effects of diuretics locally target the renal system's funct
@anchor drugs-substances
### %Substances
The full list of drugs available in the data library can be found in Table&nbsp;5 in the Validation section. Additional substances, such as oxygen, carbon dioxide, and hemoglobin that are available in the engine can be found in the @ref BloodChemistryMethodology.
The full list of drugs available in the data library can be found in Table 5 in the Validation section. Additional substances, such as oxygen, carbon dioxide, and hemoglobin that are available in the engine can be found in the @ref BloodChemistryMethodology.
@anchor drugs-variability
### Patient Variability
......@@ -249,7 +249,7 @@ The substance calculations rely on the flow values calculated by the @ref Circui
While this model is primarily used for drugs, it could be used for any substance in the body. The engine uses the clearance methodology for several additional substances. The modular approach to these calculations allows for the use of any combination of the three methodologies, PK, clearance, and PD.
The substance values and calculations are used by a variety of systems to trigger actions and responses, define physiologic set points, scale circuit parameters, and modify driver frequencies. Many of these triggers and responses are discussed in the @ref BloodChemistryMethodology and the @ref EndocrineMethodology. The drug-specific effects are listed and described briefly in Table&nbsp;5. The implementation of these calculated responses can be found in the @ref CardiovascularMethodology and the @ref RespiratoryMethodology.
The substance values and calculations are used by a variety of systems to trigger actions and responses, define physiologic set points, scale circuit parameters, and modify driver frequencies. Many of these triggers and responses are discussed in the @ref BloodChemistryMethodology and the @ref EndocrineMethodology. The drug-specific effects are listed and described briefly in Table 5. The implementation of these calculated responses can be found in the @ref CardiovascularMethodology and the @ref RespiratoryMethodology.
@anchor drugs-assumptions
### Assumptions and Limitations
......@@ -294,7 +294,7 @@ Validation - Actions
All drugs in the data library were validated qualitatively or with subject matter expert input. The bolus injection methodology was validated by comparing the PK and PD results to literature. See the sections below for more detail.
The succinycholine scenario shows a drug impacting the major engine systems. Succinycholine (Figure&nbsp;4) initially drops the heart rate and blood pressure approximately 5&ndash;10%. As expected, the respiration drops to zero within 60&ndash;90 seconds to represent the paralysis associated with the neuromuscular blocker. The oxygen saturation drops slowly as the concentration of oxygen in the bloodstream drops, leading to hypoxia. Epinephrine is released in response to hypoxia, causing an increase in heart rate and blood pressure (@ref EndocrineMethodology). This is an example of the interdependent nature of the engine systems and the chain reaction drug administration can cause.
The succinycholine scenario shows a drug impacting the major engine systems. Succinycholine (Figure 1) initially drops the heart rate and blood pressure approximately 5-10%. As expected, the respiration drops to zero within 60-90 seconds to represent the paralysis associated with the neuromuscular blocker. The oxygen saturation drops slowly as the concentration of oxygen in the bloodstream drops, leading to hypoxia. Epinephrine is released in response to hypoxia, causing an increase in heart rate and blood pressure (@ref EndocrineMethodology). This is an example of the interdependent nature of the engine systems and the chain reaction drug administration can cause.
<center>
<table border="0">
......@@ -312,7 +312,7 @@ The succinycholine scenario shows a drug impacting the major engine systems. Suc
</table>
</center>
<center>
<i>Figure 2. The neuromuscular blocker, Succinylcholine, causes a cessation of respiration due to its paralytic effects. The heart rate and blood pressure initially decrease due to the system-level drug effects. As the oxygen decreases, hypoxia occurs, resulting in an increase in heart rate and blood pressure.</i>
<i>Figure 1. The neuromuscular blocker, Succinylcholine, causes a cessation of respiration due to its paralytic effects. The heart rate and blood pressure initially decrease due to the system-level drug effects. As the oxygen decreases, hypoxia occurs, resulting in an increase in heart rate and blood pressure.</i>
</center><br>
#### Intravenous Administration
......@@ -322,7 +322,7 @@ Validation of intravenous administration of a hypotonic solution and blood produ
Validation - Pharmacokinetic
--------------------
The PK model was validated by comparing the plasma concentration calculated by the engine to plasma concentration curves found in the literature. The comparisons are shown in Figures 4&ndash;14. No available data was found for Epinephrine, so this drug was only validated from a PD perspective.
The PK model was validated by comparing the plasma concentration calculated by the engine to plasma concentration curves found in the literature. The comparisons are shown in Figures 4-14. No available data was found for Epinephrine, so this drug was only validated from a PD perspective.
<img src="./plots/Drugs/Albuterol.jpg" width="1100">
<center>
......@@ -390,7 +390,7 @@ The above results show that, in general, the model chosen for the engine produce
Validation - Pharmacodynamic
--------------------
The pharmacodynamic effects of the drugs were validated by comparing the effects of each drug to a number of clinical parameters. A summary of the drug validation is shown in Table&nbsp;5. More details on the individual scenario validation can be found in the <a href="DrugsValidation.pdf">Drugs Scenario Validation Matrix</a>.
The pharmacodynamic effects of the drugs were validated by comparing the effects of each drug to a number of clinical parameters. A summary of the drug validation is shown in Table 5. More details on the individual scenario validation can be found in the <a href="DrugsValidation.pdf">Drugs Scenario Validation Matrix</a>.
<center>
<i>Table 5. The engine drug library was validated qualitatively with published values and using subject matter expertise. Green indicates good agreement with validation data, yellow indicates agreement with a general trend with some minor disagreement, and red indicates a disagreement with the validation data. The number indicates the number of output parameters for each category of validation success or failure.</i>
......@@ -479,7 +479,7 @@ PD effects for the diuretic Furosemide are handled differently than other drugs
Conclusions
-----------
In general, the drugs in the data library have strong agreement with both the published data and subject matter expertise. The biggest limitation lies in the transient response to drugs. Currently, the system tolerances provide a response within 30&ndash;60 seconds for all drugs, regardless of the physiologic onset time. The drug response also wears off quickly for all drugs. It is difficult to specify the desired pharmacodynamic response without a well thought out set of parameters. These issues will be addressed as part of future work on the engine by validating the pharmacokinetic model and implementing and validating a pharmacodynamic model.
In general, the drugs in the data library have strong agreement with both the published data and subject matter expertise. The biggest limitation lies in the transient response to drugs. Currently, the system tolerances provide a response within 30-60 seconds for all drugs, regardless of the physiologic onset time. The drug response also wears off quickly for all drugs. It is difficult to specify the desired pharmacodynamic response without a well thought out set of parameters. These issues will be addressed as part of future work on the engine by validating the pharmacokinetic model and implementing and validating a pharmacodynamic model.
These models and the combination of these models represent a positive step forward for drug simulation. The parameters are intuitive and accurate for each drug and additional drugs can be added for an expanded drug library.
......
......@@ -64,11 +64,11 @@ Epinephrine is released by the adrenal medulla at a basal endogenous rate of app
Two stimuli, exercise and acute stress, can modify the epinephrine release rate.
#### Exercise
The increase in epinephrine release as a function of above-basal exercise was developed using data in @cite stratton1985hemodynamic and @cite tidgren1991renal. We assume that the epinephrine clearance rate is constant; therefore, the fractional increase in epinephrine concentration described in @cite stratton1985hemodynamic and @cite tidgren1991renal can be assumed to be due to a similar fractional increase in release rate. Using that assumption, we fit a logistic function to the basal-normalized epinephrine steady-state concentrations during exercise presented in @cite tidgren1991renal. The release modifier varies from 1 to 19.75, as shown in Figure 2, meaning that the epinephrine release rate will be 19.75 times the basal release rate with maximal exercise. The model is implemented by first computing the above-basal metabolic rate and then using the generic logistic function with the appropriate parameter values to compute the release rate multiplier.
The increase in epinephrine release as a function of above-basal exercise was developed using data in @cite stratton1985hemodynamic and @cite tidgren1991renal. We assume that the epinephrine clearance rate is constant; therefore, the fractional increase in epinephrine concentration described in @cite stratton1985hemodynamic and @cite tidgren1991renal can be assumed to be due to a similar fractional increase in release rate. Using that assumption, we fit a logistic function to the basal-normalized epinephrine steady-state concentrations during exercise presented in @cite tidgren1991renal. The release modifier varies from 1 to 19.75, as shown in Figure 1, meaning that the epinephrine release rate will be 19.75 times the basal release rate with maximal exercise. The model is implemented by first computing the above-basal metabolic rate and then using the generic logistic function with the appropriate parameter values to compute the release rate multiplier.
<img src="./plots/Endocrine/EpiExercise.jpg" width="600">
<center>
*Figure 2. The increase in epinephrine release during exercise is computed as a fraction of the basal rate.*
*Figure 1. The increase in epinephrine release during exercise is computed as a fraction of the basal rate.*
</center><br>
......@@ -112,7 +112,7 @@ Validation - Actions
--------------------------------------
@anchor endocrine-acute-stress
### Acute Stress
The effects of epinephrine release on the physiology can be clearly seen by triggering an Acute Stress action. The patient in this scenario undergoes three bouts of Acute Stress, with the first representing mild pain, the second representing mental stress, and the third representing a panic attack. The severity levels were chosen by checking the blood concentration of epinephrine to ensure it met published values. However, a known issue with epinephrine modeling in the current engine release is that higher concentrations of epinephrine are needed to produce the effects noted in literature. In order to achieve the physiological effects, the severity was proportionally scaled up. This shortcoming is the reason for the failing epinephrine concentrations, but it allows for the other effects of epinephrine to be modeled, which has beneficial effects for other systems utilizing epinephrine. Heart rate behaves as expected, but blood pressure effects aren't always in line with expectations. This is likely an effect of baroreceptor reflex counterbalancing epinephrine effects. Figure 3 shows the blood concentration and select effects with the acute stress action.
The effects of epinephrine release on the physiology can be clearly seen by triggering an Acute Stress action. The patient in this scenario undergoes three bouts of Acute Stress, with the first representing mild pain, the second representing mental stress, and the third representing a panic attack. The severity levels were chosen by checking the blood concentration of epinephrine to ensure it met published values. However, a known issue with epinephrine modeling in the current engine release is that higher concentrations of epinephrine are needed to produce the effects noted in literature. In order to achieve the physiological effects, the severity was proportionally scaled up. This shortcoming is the reason for the failing epinephrine concentrations, but it allows for the other effects of epinephrine to be modeled, which has beneficial effects for other systems utilizing epinephrine. Heart rate behaves as expected, but blood pressure effects aren't always in line with expectations. This is likely an effect of baroreceptor reflex counterbalancing epinephrine effects. Figure 2 shows the blood concentration and select effects with the acute stress action.
<center>
<table border="0">
......@@ -130,7 +130,7 @@ The effects of epinephrine release on the physiology can be clearly seen by trig
</table>
</center>
<center><i>
*Figure 3. Epinephrine is released in response to Acute Stress actions.*
*Figure 2. Epinephrine is released in response to Acute Stress actions.*
</i>
</center><br>
......
......@@ -125,7 +125,7 @@ Features, Capabilities, and Dependencies
@image html GICircuit.png
<center>
<i>
Figure 4. The %GI circuit is made up of nodes and paths with elements and is connected to extravascular tissue and the cardiovascular system.
Figure 2. The %GI circuit is made up of nodes and paths with elements and is connected to extravascular tissue and the cardiovascular system.
</i>
</center><br>
......
......@@ -46,8 +46,6 @@ Initialize, setup, tune, conditions, stabilization, etc.
### Assessments
Include a data flow diagram.
Features and Capabilities
-------------------------
......
......@@ -84,7 +84,7 @@ Where &nu; is a parameter that represents the response slope of the baroreceptor
<img src="./plots/Nervous/Response_Fractions.jpg" width="550">
<center>
*Figure 2. The sympathetic and parasympatheric response fractions are displayed as a function of mean arterial pressure (MAP). Both fractional forms show asymptotic behavior as divergence from the MAP set-point occurs. The response fractions are additive, always summing to a value of 1.0. At homeostasis (MAP equal to the set-point), the fractions are both equal to 0.5.*
*Figure 1. The sympathetic and parasympatheric response fractions are displayed as a function of mean arterial pressure (MAP). Both fractional forms show asymptotic behavior as divergence from the MAP set-point occurs. The response fractions are additive, always summing to a value of 1.0. At homeostasis (MAP equal to the set-point), the fractions are both equal to 0.5.*
</center><br>
As described in the [cardiovascular](@ref cardiovascular-initialize) methodology report, the %cardiovascular system is initialized according to patient definitions and the stabilized to a homeostatic state. The set-point is the resultant mean arterial pressure following the engine stabilization period. The set-point is adjusted dynamically with certain actions and insults, as shown in Equation 3.
......
......@@ -4,11 +4,13 @@
@anchor patient-overview
Overview
========
========
Abstract
--------
The engine allows for patient variability via a set of parameters used to define aspects of the simulated human. These parameters are used throughout the system models to manipulate the physiological responses and homeostatic state. The code base contains several defined patients created for various testing and analysis purposes.
@anchor patient-intro
Introduction
------------
......@@ -78,7 +80,11 @@ Features and Capabilities
### Stabilization
All patient parameters are set at the beginning of the resting stabilization period (see @ref SystemMethodology). These values are used to modify the inner workings of systems. The complex interactions require a simulated period to allow everything to balance into a stable, homeostatic, healthy starting point. After each stabilization period (i.e., resting, conditions, and feedback), several parameters are reset due to their reliance on combined effects. The patient definition only allows for healthy values - any chronic pathophysiology needs to be handled using the CDM condition definition.
There are two complete sets of patient parameters stored in the data model:
1. <i>Initial Patient</i>: These are the healthy patient parameters before any conditions or action are applied. All patient parameters are set at the beginning of the resting stabilization period (see @ref SystemMethodology). These values are used to modify the inner workings of systems. The complex interactions require a simulated period to allow everything to balance into a stable, homeostatic, healthy starting point. These parameters should not be changed during a simulation.
2. <i>Current Patient</i>: After each stabilization period (i.e., resting, conditions, and feedback), several parameters are reset due to their reliance on combined effects. These parameters can further be changed during a simulation.
While every effort has been made to allow any combination of patient parameters within bounds, there is no guarantee that all combinations will be able to reach a stable starting homeostatic point.
......
......@@ -142,7 +142,7 @@ The transport of substances is a combination of the generic methodology and acti
Data Flow
---------
The %Renal System determines its state at every time step through a three-step process: Preprocess, Process, and Postprocess (Figure 3). In general, Preprocess sets the circuit element values based on feedback mechanisms and engine settings/actions. Process uses the generic circuit calculator to compute the entire state of the circuit. Postprocess is used to advance time. More specifics about these steps are detailed below.
The %Renal System determines its state at every time step through a three-step process: Preprocess, Process, and Postprocess. In general, Preprocess sets the circuit element values based on feedback mechanisms and engine settings/actions. Process uses the generic circuit calculator to compute the entire state of the circuit. Postprocess is used to advance time. More specifics about these steps are detailed below.
### Reset, Conditions, and Initialization
......
This diff is collapsed.
......@@ -58,7 +58,7 @@ Plotter=com.kitware.physiology.utilities.csv.plots.RespiratoryPFTPlotter
##### Blood Chemistry Methodology Report #####
HemorrhageClass2Saline=ActionEventPlotter RemoveLegends NoGrid Title=Volume Header=BloodVolume(L) OutputOverride=./docs/html/plots/BloodChemistry ImageDimensions=1100,400
HemorrhageClass2Saline=ActionEventPlotter RemoveLegends NoGrid Title=Hemoglobin Header=HemoglobinContent(g) OutputOverride=./docs/html/plots/BloodChemistry ImageDimensions=1100,400
HemorrhageClass2Saline=ActionEventPlotter Header=BloodVolume(L) VerificationDir=patient OutputOverride=./docs/html/plots/BloodChemistry LegendOnly NoEvents Title=BloodChemistryLegend ImageDimensions=1500,200
HemorrhageClass2Saline=ActionEventPlotter Header=BloodVolume(L) VerificationDir=patient OutputOverride=./docs/html/plots/BloodChemistry LegendOnly NoEvents Title=BloodChemistryLegend ImageDimensions=1600,200
##### Cardiovascular Methodology Report #####
# Elastance/Compliance plot (Figure 4)
......@@ -105,12 +105,12 @@ Succinylcholine=ActionEventPlotter RemoveLegends Title=Succinylcholine_HeartRate
Succinylcholine=ActionEventPlotter RemoveLegends Title=Succinylcholine_MeanArterialPressure NoGrid Header=MeanArterialPressure(mmHg) VerificationDir=drug OutputOverride=./docs/html/plots/Drugs ImageDimensions=1100,700
Succinylcholine=ActionEventPlotter RemoveLegends Title=Succinylcholine_RespirationRate NoGrid Header=RespirationRate(1/min) VerificationDir=drug OutputOverride=./docs/html/plots/Drugs ImageDimensions=1100,700
Succinylcholine=ActionEventPlotter RemoveLegends Title=Succinylcholine_OxygenSaturation NoGrid Header=OxygenSaturation VerificationDir=drug OutputOverride=./docs/html/plots/Drugs ImageDimensions=1100,700
Succinylcholine=ActionEventPlotter Header=OxygenSaturation VerificationDir=drug OutputOverride=./docs/html/plots/Drugs LegendOnly NoEvents Title=SuccinylcholineLegend ImageDimensions=2300,240
Succinylcholine=ActionEventPlotter Header=OxygenSaturation VerificationDir=drug OutputOverride=./docs/html/plots/Drugs LegendOnly Title=SuccinylcholineLegend ImageDimensions=2300,240
Furosemide=ActionEventPlotter RemoveLegends Title=Furosemide_BloodVolume NoGrid Header=BloodVolume(L) VerificationDir=drug OutputOverride=./docs/html/plots/Drugs ImageDimensions=1100,700
Furosemide=ActionEventPlotter RemoveLegends Title=Furosemide_UrineProductionRate NoGrid Header=UrineProductionRate(mL/min) VerificationDir=drug OutputOverride=./docs/html/plots/Drugs ImageDimensions=1100,700
Furosemide=ActionEventPlotter RemoveLegends Title=Furosemide_SodiumClearance NoGrid Header=Sodium-Clearance-RenalExcretionRate(g/day) VerificationDir=drug OutputOverride=./docs/html/plots/Drugs ImageDimensions=1100,700
Furosemide=ActionEventPlotter RemoveLegends Title=Furosemide_ChlorideClearance NoGrid Header=Chloride-Clearance-RenalExcretionRate(g/day) VerificationDir=drug OutputOverride=./docs/html/plots/Drugs ImageDimensions=1100,700
Furosemide=ActionEventPlotter Header=BloodVolume(L) VerificationDir=drug OutputOverride=./docs/html/plots/Drugs LegendOnly NoEvents Title=FurosemideLegend ImageDimensions=800,200
Furosemide=ActionEventPlotter Header=BloodVolume(L) VerificationDir=drug OutputOverride=./docs/html/plots/Drugs LegendOnly Title=FurosemideLegend ImageDimensions=800,200
##### Endocrine Methodology Report #####
AcuteStress=ActionEventPlotter header=Aorta-Epinephrine-Concentration(ug/L) OutputOverride=./docs/html/plots/Endocrine/ Title=Epinephrine_Blood_Concentration RemoveLegends OutputFilename=AcuteStressBloodEpi.jpg
......@@ -124,12 +124,12 @@ EpiExercise=MultiPlotter Y1=ReleaseMultiplier X1=Exercise(W) Title=None RemoveLe
ColdWaterSubmersion=ActionEventPlotter NoGrid RemoveLegends Header=TotalMetabolicRate(W) Title=TotalMetabolicRate VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy ImageDimensions=1900,500 OutputFilename=ColdWaterSubmersion_TotalMetabolicRate.jpg
ColdWaterSubmersion=ActionEventPlotter NoGrid RemoveLegends Header=CoreTemperature(degC) Title=CoreTemperature VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy ImageDimensions=1900,500 OutputFilename=ColdWaterSubmersion_CoreTemp.jpg
ColdWaterSubmersion=ActionEventPlotter NoGrid RemoveLegends Header=SkinTemperature(degC) Title=SkinTemperature VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy ImageDimensions=1900,500 OutputFilename=ColdWaterSubmersion_SkinTemp.jpg
ColdWaterSubmersion=ActionEventPlotter Header=TotalMetabolicRate(W) VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy LegendOnly NoEvents Title=ColdWaterSubmersionLegend ImageDimensions=2500,450
ColdWaterSubmersion=ActionEventPlotter Header=TotalMetabolicRate(W) VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy LegendOnly NoEvents Title=ColdWaterSubmersionLegend ImageDimensions=2000,480
HighAltitudeEnvironmentChange=ActionEventPlotter NoGrid RemoveLegends Header=OxygenSaturation Title=OxygenSaturation VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy ImageDimensions=1100,700 OutputFilename=HighAltitude_O2Sat.jpg
HighAltitudeEnvironmentChange=ActionEventPlotter NoGrid RemoveLegends Header=RespirationRate(1/min) Title=RespirationRate VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy ImageDimensions=1100,700 OutputFilename=HighAltitude_RR.jpg
HighAltitudeEnvironmentChange=ActionEventPlotter NoGrid RemoveLegends Header=HeartRate(1/min) Title=HeartRate VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy ImageDimensions=1100,700 OutputFilename=HighAltitude_HR.jpg
HighAltitudeEnvironmentChange=ActionEventPlotter NoGrid RemoveLegends Header=Aorta-Oxygen-PartialPressure(mmHg) Title=OxygenPressure VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy ImageDimensions=1150,700 OutputFilename=HighAltitude_O2PP.jpg
HighAltitudeEnvironmentChange=ActionEventPlotter Header=OxygenSaturation VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy LegendOnly NoEvents Title=HighAltitudeLegend ImageDimensions=3000,450
HighAltitudeEnvironmentChange=ActionEventPlotter NoGrid RemoveLegends Header=Aorta-Oxygen-PartialPressure(mmHg) Title=OxygenPressure VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy ImageDimensions=1100,700 OutputFilename=HighAltitude_O2PP.jpg
HighAltitudeEnvironmentChange=ActionEventPlotter Header=OxygenSaturation VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Energy LegendOnly NoEvents Title=HighAltitudeLegend ImageDimensions=650,450
##### Environment Methodology Report #####
FireFighter=ActionEventPlotter Header=ExpiratoryFlow(L/s) VerificationDir=energyenvironment Title=ExpiratoryFlowBefore(L/s) X1LowerBound=11.2 X1UpperBound=17.21 Y1Label=ExpiratoryFlow(L/s) OutputOverride=./docs/html/plots/Environment RemoveLegends
......@@ -185,12 +185,12 @@ HemorrhageClass4NoFluid=ActionEventPlotter NoGrid Title=None ImageDimensions=800
HemorrhageClass4NoFluid=ActionEventPlotter NoGrid Title=None ImageDimensions=800,400 FontSize=17 Header=GlomerularFiltrationRate(mL/min) VerificationDir=patient RemoveLegends OutputOverride=./docs/html/plots/Renal/ OutputFilename=HemorrhageGFR.jpg
HemorrhageClass4NoFluid=ActionEventPlotter NoGrid Title=None ImageDimensions=800,400 FontSize=17 Header=RenalBloodFlow(L/min) VerificationDir=patient RemoveLegends OutputOverride=./docs/html/plots/Renal/ OutputFilename=HemorrhageRBF.jpg
HemorrhageClass4NoFluid=ActionEventPlotter NoGrid Title=None ImageDimensions=800,400 FontSize=17 Header=RightAfferentArterioleResistance(mmHg_min/mL) VerificationDir=patient RemoveLegends OutputOverride=./docs/html/plots/Renal/ OutputFilename=HemorrhageArterioleResistance.jpg
HemorrhageClass4NoFluid=ActionEventPlotter LegendOnly ActionsOnly Header=RightAfferentArterioleResistance(mmHg_min/mL) Title=HemorrhageClass4NoFluidLegend VerificationDir=patient OutputOverride=./docs/html/plots/Renal/ NoEvents ImageDimensions=900,150
HemorrhageClass4NoFluid=ActionEventPlotter LegendOnly ActionsOnly Header=RightAfferentArterioleResistance(mmHg_min/mL) Title=HemorrhageClass4NoFluidLegend VerificationDir=patient OutputOverride=./docs/html/plots/Renal/ NoEvents ImageDimensions=900,160
HighAltitudeEnvironmentChange=ActionEventPlotter NoGrid Title=None NoActions Header=MeanArterialPressure(mmHg) VerificationDir=energyenvironment FontSize=17 RemoveLegends ImageDimensions=800,400 OutputOverride=./docs/html/plots/Renal/ OutputFilename=AltitudeMAP.jpg
HighAltitudeEnvironmentChange=ActionEventPlotter NoGrid NoActions Title=None Header=GlomerularFiltrationRate(mL/min) VerificationDir=energyenvironment FontSize=17 RemoveLegends ImageDimensions=800,400 OutputOverride=./docs/html/plots/Renal/ OutputFilename=AltitudeGFR.jpg
HighAltitudeEnvironmentChange=ActionEventPlotter NoGrid NoActions Title=None Header=RenalBloodFlow(L/min) VerificationDir=energyenvironment RemoveLegends FontSize=17 OutputOverride=./docs/html/plots/Renal/ ImageDimensions=800,400 OutputFilename=AltitudeRBF.jpg
HighAltitudeEnvironmentChange=ActionEventPlotter NoGrid NoActions Title=None Header=RightAfferentArterioleResistance(mmHg_min/mL) VerificationDir=energyenvironment FontSize=17 RemoveLegends OutputOverride=./docs/html/plots/Renal/ ImageDimensions=800,400 OutputFilename=AltitudeArterioleResistance.jpg
HighAltitudeEnvironmentChange=ActionEventPlotter LegendOnly NoActions Header=RightAfferentArterioleResistance(mmHg_min/mL) Title=HighAltitudeEnvironmentChangeLegend VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Renal/ NoEvents ImageDimensions=2500,500
HighAltitudeEnvironmentChange=ActionEventPlotter LegendOnly NoActions Header=RightAfferentArterioleResistance(mmHg_min/mL) Title=HighAltitudeEnvironmentChangeLegend VerificationDir=energyenvironment OutputOverride=./docs/html/plots/Renal/ NoEvents ImageDimensions=800,400
12hrFast=ActionEventPlotter Header=Bladder-Volume(mL) VerificationDir=miscellaneous RemoveLegends OutputOverride=./docs/html/plots/Renal OutputFilename=12hr_Urination.jpg
RenalTGFFeedbackOutput=MultiPlotter Y1=GlomerularFiltrationRate(L/min) FontSize=34 X1=MeanArterialPressure(mmHg) Title=None ValidationData=Renal/MAP_vs_GFR.csv DataPathVerificationOverride=unit_tests/pulse/ X2=MeanArterialPressure(mmHg) OutputOverride=./docs/html/plots/Renal/ Y2=GlomerularFiltrationRate(L/min) X1LowerBound=60 X1UpperBound=200 Y1LowerBound=.09 Y2LowerBound=.09 Y1UpperBound=.16 Y2UpperBound=.16 OutputOverride=./docs/html/plots/Renal/ NoGrid RemoveLegends DataFileOverride=RenalTGFFeedbackOutput.csv OutputFilename=MAP_vs_GFR.jpg
RenalTGFFeedbackOutput=MultiPlotter Y1=RenalBloodFlow(L/min) X1=MeanArterialPressure(mmHg) Title=None FontSize=34 ValidationData=Renal/MAP_vs_RBF.csv DataPathVerificationOverride=unit_tests/pulse/ X2=MeanArterialPressure(mmHg) Y2=RenalBloodFlow(L/min) X1LowerBound=60 X1UpperBound=200 Y1LowerBound=1 Y2LowerBound=1 Y1UpperBound=1.7 Y2UpperBound=1.7 OutputOverride=./docs/html/plots/Renal/ NoGrid RemoveLegends OutputOverride=./docs/html/plots/Renal/ DataFileOverride=RenalTGFFeedbackOutput.csv OutputFilename=MAP_vs_RBF.jpg
......
Markdown is supported
0% or .
You are about to add 0 people to the discussion. Proceed with caution.
Finish editing this message first!
Please register or to comment